QIAGEN/QGEN

$40.00

1.34%
-
1D1W1MYTD1YMAX

About QIAGEN

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Ticker

QGEN

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Thierry Bernard

Employees

5,967

Headquarters

Venlo, Netherlands

QIAGEN Metrics

BasicAdvanced
$8.68B
Market cap
25.71
P/E ratio
$1.53
EPS
0.44
Beta
-
Dividend rate
$8.68B
0.44302
$47.74
$34.77
1.06M
1.99
1.621
24.209
39.65
23.801
5.5%
9.38%
6.6%
25.713
4.419
2.281
10.785
29.273
-8.23%
-19.52%
1.66%
-1.18%

What the Analysts think about QIAGEN

Analyst Ratings

Majority rating from 19 analysts.
Buy

Price Targets

Average projection from 15 analysts.
27.48% upside
High $60.00
Low $43.81
$40.00
Current price
$50.99
Average price target

QIAGEN Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
19.17% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$509.1M
7%
Net income
$97.6M
25.45%
Profit margin
19.17%
17.25%

QIAGEN Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0.26%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.53
$0.53
$0.52
$0.55
-
Expected
$0.48
$0.52
$0.50
$0.55
$0.44
Surprise
9.23%
1.14%
3.47%
-0.26%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for QIAGEN stock?

QIAGEN (QGEN) has a market cap of $8.68B as of April 21, 2024.

What is the P/E ratio for QIAGEN stock?

The price to earnings (P/E) ratio for QIAGEN (QGEN) stock is 25.71 as of April 21, 2024.

Does QIAGEN stock pay dividends?

No, QIAGEN (QGEN) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next QIAGEN dividend payment date?

QIAGEN (QGEN) stock does not pay dividends to its shareholders.

What is the beta indicator for QIAGEN?

QIAGEN (QGEN) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the QIAGEN stock price target?

The target price for QIAGEN (QGEN) stock is $50.99, which is 27.48% above the current price of $40. This is an average based on projections from 15 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell QIAGEN stock

Buy or sell QIAGEN stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing